AHA yesterday commented on recent Medicare Payment Advisory Commission discussions on possible approaches to reducing spending on Part B drugs and biologicals, improving alternative payment models, and revising the hospital wage index. The letter raises concerns with approaches that would shift responsibility for surging drug prices from drug manufacturers to hospitals and patients. Instead, it supports a cap on average sales price inflation that requires drug manufacturers to pay rebates to the federal government when ASP growth exceeds an inflation benchmark, and encourages the commission to further evaluate a payment model that implements mandatory additional rebates to purchasers when the manufacturer’s price increase for a Part B drug exceeds inflation. The letter also raises concerns with possible approaches that would use non-hospital data to calculate the wage index. In addition, AHA voiced support for exploring how a multi-track APM could “provide a glide path to risk for all potential participants” to ensure “a balance between incentivizing participation in models and securing cost savings and high-quality care for patients.” 

Related News Articles

Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…